Sanofi-aventis enters into an Exclusive Global Licensing Agreement with The Rockefeller University

sanofi-aventisSanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced an exclusive global licensing agreement with The Rockefeller University (New York, NY) concerning a novel monoclonal antibody, targeting certain specific forms of the Amyloid Beta parenchymal plaque for the treatment of Alzheimer's disease.

The anti-Amyloid Beta (ABeta) antibody therapy is a highly attractive approach to prevent and reverse the amyloid plaque formation which may lead to cognitive improvement in patients with Alzheimer's disease. This antibody is planned to enter development at the end of 2009.

"It's a great pleasure to interact with The Rockefeller University and in particular with Dr. Jeffrey Ravetch, a worldwide expert in the engineering of mAb Fc region and effector functions," declared Marc Cluzel, Executive Vice-President, R&D, sanofi-aventis. "Dr Ravetch discovered the original murine monoclonal antibody targeting the Amyloid Beta peptide, one target which may have a significant positive impact in the management of patients with Alzheimer's disease, which is a public health priority."

"I am pleased to contribute with sanofi-aventis to the development of a novel anti-ABeta antibody for the treatment of Alzheimer's Disease" said Dr. Jeffrey Ravetch - Professor and Head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology at The Rockefeller University. "The initial studies suggest that this antibody may be an effective means of reducing the progression of this widespread and debilitating disease."

Under the terms of the agreement, sanofi-aventis will obtain an exclusive worldwide license to develop, manufacture and commercialize the anti-ABeta antibody. The terms of such license are undisclosed.

About Alzheimer's disease
Alzheimer's disease is a progressive, degenerative disease of the brain, which causes thinking and memory to become seriously impaired. It is the most common form of dementia, a syndrome consisting of a number of symptoms that include loss of memory, judgment and reasoning, and changes in mood, behavior and communication abilities. Generally, it is diagnosed in people over 65 years of age, although the less-prevalent early-onset Alzheimer's can occur much earlier. In 2009, the reported prevalence of Alzheimer's is 35 million worldwide and to strongly increase in the next decades due to ageing population.

About Amyloid Beta (ABeta) and Alzheimer's disease
One of the hallmarks of Alzheimer's disease is the accumulation of amyloid plaques between nerve cells (neurons) in the brain. Amyloid is a general term for protein fragments that the body produces normally. Amyloid Beta is a protein fragment snipped from an Amyloid Precursor Protein (APP). In a healthy brain, these protein fragments are broken down and eliminated. In Alzheimer's disease, the fragments accumulate to form hard, insoluble plaques.

About The Rockefeller University
The Rockefeller University is a world-renowned center for research and graduate education in the biomedical sciences, chemistry, and physics. Founded by John D. Rockefeller in 1901, the university has been the site of many important scientific breakthroughs. Rockefeller scientists established that DNA is the chemical basis of heredity, discovered blood groups, showed that viruses can cause cancer, founded the modern field of cell biology, and worked out the structure of antibodies. Twenty-three Nobel Prize winners have been associated with the university.

About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Most Popular Now

Delivering insulin in a pill

Given the choice of taking a pill or injecting oneself with a needle, most of us would opt to regulate a chronic health condition by swallowing a pill. But for millions o...

Can aspirin treat Alzheimer's?

A regimen of low-dose aspirin potentially may reduce plaques in the brain, which will reduce Alzheimer's disease pathology and protect memory, according to neurological r...

Probiotics can protect the skeletons of older wome…

For the first time in the world, researchers at the University of Gothenburg, Sweden, have demonstrated that probiotics, dietary supplements with health-promoting bacteri...

Alzheimer's breakthrough: Brain metals that may dr…

Alzheimer's disease could be better treated, thanks to a breakthrough discovery of the properties of the metals in the brain involved in the progression of the neurodegen...

FDA approves first drug comprised of an active ing…

The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms o...

Researchers develop a new method for turning skin …

Our bodies consist of many different kinds of cells, each with their own role. The Japanese scientist Shinya Yamanaka had made earlier the discovery, earning the Nobel Pr...

Some existing anti-cancer drugs may act in part by…

Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti...

FDA takes steps to foster greater efficiency in bi…

Today, the agency withdrew the draft guidance, "Statistical Approaches to Evaluate Analytical Similarity," issued in September 2017. The draft guidance, if finalized as w...

Poliovirus therapy for recurrent glioblastoma has …

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, wit...

Novartis Clear about Psoriasis survey data highlig…

Novartis announced today the publication of global Clear about Psoriasis survey data in the Journal of the European Academy of Dermatology and Venereology[1]. The publica...

Human clinical trial reveals verapamil as an effec…

Researchers at the University of Alabama at Birmingham Comprehensive Diabetes Center have discovered a safe and effective novel therapy to reduce insulin requirements and...

How targeting metabolism can defeat cancer stem ce…

Researchers are the University of Michigan Rogel Cancer are unraveling a crucial thread that explains why cancer so often becomes resistant to treatment. In a breakthroug...